These health startups raised $124M in venture capital funding this week
Although the Covid-19 pandemic has continued its relentless spread across the globe, several startup companies have closed venture capital funding rounds this week.
Amphivena raises $62M Series C round to develop bispecific antibody in solid tumors
The company presented data from a Phase I study in acute myeloid leukemia at the European Hematology Association's annual meeting during the summer.
presented by
The Top Appointment Scheduling Software for Wellness Clinics
Scheduling software is helpful for wellness business owners in numerous ways. They get everything they need to create appointments, reschedule clients and track cancellations in one platform.
Frontier Medicines launches with $67M Series A, hopes to go after ‘undruggable’ targets
Many proteins known to play roles in cancers are considered "undruggable" because they lack pockets for drugs to bind to. Amgen drew attention at ASCO with data on a drug targeting a KRAS mutation, generally considered not amenable to pharmaceutical therapy.
ElevateBio launches with $150M Series A – to launch cell and gene therapy companies
The firm will follow a model similar to that of BridgeBio, partnering with scientific researchers and launching companies to develop and commercialize their products.
MPM Capital raises $400M in seventh venture fund
The company plans to invest the money across several therapeutic areas and modalities, including oncology, immunology, gene and cell therapies.
Harpoon Therapeutics raises $70M Series C for T-cell engager therapies
The company is currently running a Phase I study in prostate cancer and plans to advance additional therapies into Phase I trials and IND-enabling studies next year.
presented by
Immune Support on Demand: Ranking the Top Mobile IV Therapy Companies
Explore the top mobile IV therapy companies boosting immune health on demand, with standout services, expert care and innovative delivery across the U.S.
Vascular Pharmaceuticals announces $9M expansion of Series A financing
The mission to move forward with addressing complications for diabetic patients, specifically diabetic nephropathy that leads to kidney disease, continues Tuesday with an increase in Series A funding (a $9 million addition that brings the total to $25 million) for the clinical-stage pharmaceutical company Vascular Pharmaceuticals, Inc. (VPI). According to a press release, existing investors […]
Novartis buys cancer immunotherapy startup co-founded by venture investors
A biotechnology company formed by two MPM Capital managing directors to develop monoclonal antibody drugs to fight cancer has been acquired by Novartis, according to a company statement. The move follows Novartis’ deal with University of Pennsylvania to collaborate on chimeric antigen receptor technology and reflects a relatively dramatic shift in the past year toward […]
EnteroMedics in full fundraising mode; offers to sell 12M shares
Hoping to push its groundbreaking obesity-fighting device across the proverbial finish line, EnteroMedics Inc. (NASDAQ:ETRM) is selling 12 million new shares to the public